| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 05/31/2023 | Design Therapeutics, Inc. | DSGN | Grant | Stock Option (right to buy) | 15k | $5.63 | $84.4k | | 05/31/2023 |
| 06/15/2022 | Design Therapeutics, Inc. | DSGN | Grant | Stock Option (right to buy) | 15k | $13.69 | $205.4k | | 06/15/2022 |
| 03/22/2022 | Design Therapeutics, Inc. | DSGN | Sale | Common Stock | 1.5k | $18.63 | $27.1k | See footnote | 03/18/2022 |
| 03/21/2022 | Design Therapeutics, Inc. | DSGN | Sale | Common Stock | 24k | $19.01 | $456.2k | See footnote | 03/18/2022 |
| 03/18/2022 | Design Therapeutics, Inc. | DSGN | Sale | Common Stock | 13.2k | $20.34 | $268.5k | See footnote | 03/18/2022 |
| 03/18/2022 | Design Therapeutics, Inc. | DSGN | Sale | Common Stock | 552.2k | $19.04 | $10.5M | See footnote | 03/18/2022 |
| 07/01/2021 | Tempest Therapeutics, Inc. | OVAS | Grant | Stock Option (Right to Buy) | 6.6k | $11.07 | $73.4k | | 07/01/2021 |
| 06/25/2021 | Tempest Therapeutics, Inc. | OVAS | Grant | Common Stock | 579.7k | $0.00 | $0 | By Quan Venture Fund I, L.P. | 06/25/2021 |
| 06/24/2021 | NextCure, Inc. | NXTC | Grant | Stock Option (Right to Buy) | 14.2k | $8.21 | $117k | | 06/24/2021 |
| 03/30/2021 | Design Therapeutics, Inc. | DSGN | Conversion | Series B Preferred Stock | 458k | $0.00 | $0 | See footnote | 03/30/2021 |
| 03/30/2021 | Design Therapeutics, Inc. | DSGN | Conversion | Series A Preferred Stock | 7.2M | $0.00 | $0 | See footnote | 03/30/2021 |
| 03/30/2021 | Design Therapeutics, Inc. | DSGN | Purchase | Common Stock | 10k | $20.00 | $200k | By spouse | 03/30/2021 |
| 03/30/2021 | Design Therapeutics, Inc. | DSGN | Conversion | Common Stock | 281k | $0.00 | $0 | See footnote | 03/30/2021 |
| 03/30/2021 | Design Therapeutics, Inc. | DSGN | Conversion | Common Stock | 4.4M | $0.00 | $0 | See footnote | 03/30/2021 |
| 03/25/2021 | Design Therapeutics, Inc. | DSGN | Grant | Stock Option (right to buy) | 15k | $20.00 | $300k | | 03/25/2021 |
| 06/11/2020 | NextCure, Inc. | NXTC | Grant | Stock Option (Right to Buy) | 14.2k | $24.13 | $343.9k | | 06/11/2020 |
| 06/13/2019 | NextCure, Inc. | NXTC | Grant | Stock Option (Right to Buy) | 22k | $15.57 | $342.5k | | 06/13/2019 |
| 05/13/2019 | NextCure, Inc. | NXTC | Conversion | Common Stock | 978.6k | $0.00 | $0 | By Quan Venture Fund II, L.P. | 05/13/2019 |
| 05/13/2019 | NextCure, Inc. | NXTC | Purchase | Common Stock | 125k | $15.00 | $1.9M | By Quan Venture Fund II, L.P. | 05/13/2019 |
| 05/13/2019 | NextCure, Inc. | NXTC | Conversion | Series B-2 Preferred Stock | 7.9M | $0.00 | $0 | By Quan Venture Fund II, L.P. | 05/13/2019 |
| 06/22/2018 | ARMO BioSciences, Inc. | ARMO | Disposition | Stock Option (right to buy) | 18k | $39.97 | $719.5k | | 06/22/2018 |
| 06/22/2018 | ARMO BioSciences, Inc. | ARMO | Other | Common Stock | 404.9k | $50.00 | $20.2M | By Quan Venture Fund I, L.P. | 06/22/2018 |
| 03/26/2018 | ARMO BioSciences, Inc. | ARMO | Grant | Stock Option (right to buy) | 18k | $39.97 | $719.5k | | 03/26/2018 |
| 01/30/2018 | ARMO BioSciences, Inc. | ARMO | Conversion | Series C-1 Convertible Preferred Stock | 404.9k | $0.00 | $0 | By Quan Venture Fund I, L.P. | 01/30/2018 |
| 01/30/2018 | ARMO BioSciences, Inc. | ARMO | Conversion | Common Stock | 404.9k | $0.00 | $0 | By Quan Venture Fund I, L.P. | 01/30/2018 |